Letter from the Editor

Dear colleagues,

The annual meeting of the EADV 2022 congress was again a live and lively event, full of discovery and innovation. After the many web-conferences, the live meeting was well appreciated by thousands of European dermatologists. It was worthwhile to meet live with colleagues and to have continuing medical education with the human touch instead of the click of the mouse.

In psoriasis, systemics (the biologic bimekizumab and the small molecule deucravacitinib) and the new topicals (PDE-4 inhibitors and tapinarof) were the innovations. In atopic dermatitis, the biologics (IL-13 inhibitors and IL-22 inhibitors) and a wide range of Janus kinase inhibitors provide unprecedented introduction of new treatments.

Both in psoriasis and atopic dermatitis, there is a need to develop strategies which we collectively designated as personalised medicine. This implies the development of biomarkers.

At this EADV, the biologics and non-biologic systemics are also developed for different fields in dermatology, where innovations were more seldom: hydradenitis chronica suppurativa, vitiligo, and alopecia areata.

Also sun protection, skin cancer, and pruritus were in the spotlight as common concerns.

The present report aims to give an overview of innovations as presented at EADV 2022.

Best regards,

Peter CM van de Kerkhof

Senior professor of Dermatology, Radboud University Nijmegen Medical Centre, the Netherlands

 

Biography
Peter C.M. van de Kerkhof is emeritus Professor of Dermatology and immediate past chairman of the Department of Dermatology of Radboud University Nijmegen. He is currently the coordinating Medical Officer of the International Psoriasis Council and chair of the scientific advisory board of the Dutch burn association. He has been working for many years on the pathogenesis and treatment of psoriasis. He has published more than 700 publications in peer-reviewed journals and has given many presentations on invitation at international conferences. He has served as president of the
ESDR, EDF, and the International Psoriasis Council, and was board member of various international societies. Current interests are pathogenesis and development of biomarkers for psoriasis; real clinical practice research; and personalised medicine.

Conflict of Interest Statement: Consultancy services for: Celgene, Almirall, Amgen, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novartis, Janssen Biotech, Janssen-Cilag, LEO Pharma, Sandoz, Mitsubishi Tanabe, Bristol Meyer Squibb, UCB, Dermavant. Speaker services for: Celgene, Almirall, Eli Lilly, Novartis, Jansen-Cilag, LEO Pharma, Sandoz, Bristol Meyer Squibb.

 



Posted on 5 November, 2022